In recent years, immunotherapy for advanced melanoma has been gaining increased attention. The efficacy of anti-cytotoxic T-lymphocyte antigen 4 antibodies, anti-programmed cell death 1 antibodies and the BRAFV600E kinase inhibitor has been proven in metastatic melanoma. At the same time, adoptive cell transfer has significant effects against metastatic melanoma, however, it is difficult to apply on a broad scale because of the problems related to cell preparation. To overcome these problems, we developed immune cell therapy using induced pluripotent stem ( 
Introduction
In recent years, immunotherapy for malignant melanoma (MM) has garnered much attention the other hand, immune cell therapy has a more durable effect for metastatic melanoma (3, 4) . Cell therapies, including adoptive cell transfer (ACT), that use genetically engineered T cells (TCR/CAR), are therefore considered to be crucial to the effective treatment of melanoma patients. However, the TCR/CAR technique is difficult to apply in the clinical setting for several reasons: 1) an ideal membrane-bound melanoma-associated antigen that can be recognized by CAR is yet to be found; 2)
'neoantigens' in tumors, which can be strongly recognized by T cells, are important for a strong CTL response (5) . The neoantigens vary by individuals, necessitating TCR-transduced T cells be prepared on an individual basis; 3) TCR/CAR cells are made from autologous lymphocytes, which are isolated from the patient's peripheral blood by leukapheresis. However, this technique is sometimes difficult to apply in advanced cancer patients with bone marrow failure.
To overcome these problems associated with ACT, we have conducted a study of immune cell therapy with induced pluripotent stem (iPS) cells. The benefit of our method is that a large number of cells can be readily obtained, and these can exert additional immune functions when genetically modified.
We have established a method to differentiate iPS cell cultures to generate dendritic cells and macrophages via CD43 +
CD11b
+ myeloid precursor cells (iPS-MC) (6) . We induce the proliferation of iPS-MC by lentivirus-mediated transduction of genes that can promote cell proliferation or inhibit cell senescence, such as cMYC plus BMI1, MDM2, or EZH2, to generate iPS cell-derived myeloid cell lines (iPS-ML) (7) . The iPS-ML can proliferate for at least three months in a M-CSF-dependent manner. These iPS-ML possess the capacity to differentiate into macrophages that exhibit the morphology, molecule expression, and phagocytic activity of physiological macrophages upon treatment with M-CSF and GM-CSF (8) . Expression vectors for anticancer molecules known to induce death or inhibit the growth of cancer cells, including IFNα, IFNβ, IFNγ, TNFα, FAS-ligand, and TRAIL, can be introduced into iPS-ML via lentivirus vectors to make them efficiently attack cancer cells and overcome the influence of the tumor environment (8) . However, only the iPS-ML expressing IFNβ effectively inhibited the growth of peritoneally disseminated gastric and pancreatic cancers in xenograft models (8) .
Melanoma is one of the most aggressive cancers, responsible for most skin cancer deaths (9) . Peritoneal dissemination is often seen in MM, and is difficult to treat because surgical resection and radiation therapy are ineffective. Therefore, more potent immune therapy is urgently needed.
The efficacy of IFNs against melanoma has been known for quite some time (10, 11 However, the efficacy of IFNs for metastatic melanoma has not been studied. In contrast, local injection of IFNβ for skin metastasis is effective (10) . In addition, IFNα has been used as an adjuvant therapy after the surgical removal of primary melanoma.
High-dose IFNα adjuvant therapy showed a benefit in terms of the disease-free survival (DFS) in high-risk resected primary melanoma patients, however, grade 3/4 adverse effects occurred in 45% of patients who received long-term high-dose IFNα, and 31% of patients stopped treatment due to toxicity (12, 13) . Practitioners should be aware that elderly patients (age 65 years and older) were under-represented in the high-dose interferon trials (12) . Given the toxicities of interferon, particularly in the presence of other significant comorbidities, caution is advised (12) . It follows that although the local injection of IFN is effective and safe, and systemically-administered IFN can also be effective, systemic application is associated with potentially severe adverse effects. Therefore, we evaluated the potential of iPS-ML as anticancer effector cells with the use of genetically modified iPS-ML that expressed type I IFNs. Macrophage infiltration is frequently observed in clinical samples of cancer tissues (14) . It was expected that the iPS-ML expressing type I IFNs would be able to infiltrate into the tumor tissue and exert anticancer effects in the local tumor tissue. In this paper, we report that iPS-ML-expressing type I IFNs could exert therapeutic effects against peritoneally 
Materials and Methods

Cells and reagents
This study was approved by the ethics review board of Faculty of Life Sciences Kumamoto University. The human malignant melanoma cell line, SK-MEL28, was provided by ATCC. Cell line authentication was performed using short tandem repeat profiling and comparison with known cell line DNA profiles. SK-MEL28 cells were transduced with a lentivirus vector encoding the firefly luciferase gene as described previously (7) for the analysis based on luciferase activity.
The methods used for the generation and maintenance of human iPS cells have been described (6) .
Generation of proliferating myeloid cells from human iPS cells
The methods used for the differentiation of human iPS cells into dendritic cells (iPS-DC) and macrophages (iPS-MP) have been described (6) (iPS-MC). These iPS-MC, which possess the capacity to differentiate into DC upon treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL) 4, and the capacity to differentiate into MP in the presence of M-CSF and GM-CSF, could proliferate for seven to 14 days in the presence of GM-CSF and M-CSF, but then ceased to grow. Therefore, we introduced several genes with the potential to induce cell proliferation into the iPS-MC using lentiviruses to confer the iPS-MC with long-term proliferative capacity (7) . The cDNA fragments were inserted into the lentiviral vector CSII-EF (15) (a gift from Dr. H. Miyoshi together with the packaging constructs, RIKEN, Tsukuba, Japan), with or without IRES-puroR, to generate lentiviral expression constructs. As a consequence, we found that simultaneous introduction of cMYC, together with BMI1, MDM2 or EZH2, resulted in the continuous proliferation of iPS-MC for at least three months, and their proliferation was dependent on the addition of M-CSF. We named the iPS-MC-derived long-term proliferating cells iPS-ML (iPS cell-derived myeloid/macrophage cells) (7).
Generation of genetically modified iPS-ML-expressing type I IFNs
iPS-ML were transduced with a lentivirus vector encoding human IFNα or IFNβ as described (7, 8 in medium containing hygromycin (0.5-2 mg/mL). To quantify the production of transgene-derived cytokines, the transfected iPS-ML were cultured (1×10 5 cells/well in 200 μl) in 96-well culture plates for 24 hours, and the concentration of type I IFNs in the culture supernatant was measured using ELISA kits (Endogen or R&D Systems).
Zymosan phagocytosis assay
The phagocytic ability of the iPS-ML was analyzed using FITC-labeled zymosan A particles (Molecular Probes). The cultured iPS-ML were treated with FITC-labeled zymosan particles. After an 80-min incubation, they were observed under a microscope.
Flow cytometric analysis
We analyzed the cell surface molecule expression of iPS-ML by a flow cytometric . The mice were dissected on the following day and the greater omentum and spleen were isolated. We then analyzed the cell surface molecule expression of endogenous macrophages by a flow cytometric analysis using antibodies to mouse CD169 and CD163. We simultaneously examined control mice, which had not been intraperitoneally injected with human melanoma cells.
Colony forming cell assays
Colony forming cells (CFC) assays examined the ability of iPS-ML to proliferate and differentiate into colonies in a semi-solid media in response to cytokine stimulation. 
Statistical analysis
The statistical analyses were carried out using the Bonferroni's test. A P-value < 0.05 was considered to be statistically significant.
Results
Characterization of human iPS cell-derived myeloid cells
We analyzed the morphology and the phagocytic ability of iPS-ML. The iPS-ML had round nuclei and abundant cytoplasm (Fig. 1A) . The phagocytic ability of the iPS-ML was assessed by their ingestion of FITC-labeled zymosan A particles. The iPS-ML were cultured after adding FITC-labeled zymosan particles. After an 80-min incubation, we microscopically observed that fluorescence signals were detected in most cells, indicating that the majority of the iPS-ML ingested the zymosan particles (Fig. 1B) .
We then generated iPS-ML expressing IFNα or IFNβ (iPS-ML-IFNα, iPS-ML-IFNβ) as described (7, 8) . First, we analyzed the cell surface expression of the iPS-ML by flow cytometric analysis. The iPS-ML expressing type I IFNs expressed several macrophage markers, including CD11b, CD14, CD36, CD68, CD169, TLR-4, and CD206 (Fig. 1C) .
The iPS-ML expressing type I IFNs had increased expression of CD169, a marker of inflammatory macrophages that can activate antitumor immunity. In contrast, iPS-ML without type I IFNs had increased expression of CD206, a marker of macrophages that display a pro-tumor activity (Fig. 1C) . This indicated that the type I IFNs produced by the cells themselves could change their expression of cell surface molecules.
Macrophages are thought to be affected by the local cytokine environment and are polarized to an M1 phenotype (positive for CD169), which exerts an antitumor effect, or the M2 phenotype (positive for CD206 and/or CD163), which support tumor survival (16 -18) . The macrophages observed in clinical samples of solid cancer, called TAM (tumor-associated macrophages) (14) were affected by the cancer microenvironment and were polarized to an M2 phenotype in most cases. However, the iPS-ML expressing type I IFNs started to express CD169, indicating that the iPS-ML were polarized to an 
M1 phenotype and could exert anticancer effects. This phenotype of the iPS-ML expressing type I IFNs was durable and not affected by tumor-derived cytokines found in the cancer microenvironment, like IL10 and TGFβ in vitro (data not shown.). (Fig. 2) . Recombinant IFNβ (Fig. 2B) exhibited a more potent effect at a lower concentration than IFNα (Fig. 2A) .
Anticancer activity of iPS-ML expressing type I IFNs in vitro
We next evaluated the expression of type I IFNs by the iPS-ML with or without type I IFNs using an ELISA. The iPS-ML were cultured for 72 hours, and the concentration of type I IFNs in the culture supernatant was measured (Fig. 3A) . The iPS-ML-IFNα and β had the ability to produce IFNα and β, respectively, whereas the iPS-ML hardly produced type I IFNs. 
To examine the anti-tumor effects of iPS-ML expressing type I IFNs, the luciferase-expressing SK-MEL28 cells were cultured alone, with iPS-ML, with iPS-ML expressing type I IFNs, or with recombinant type I IFNs. The concentration of recombinant type I IFNs was decided based on the results of the ELISA of the iPS cells (Fig. 3A) . The number of live SK-MEL28 cells was again assessed by the luciferase activity after three days in culture. We observed that all treatments, including treatment with the iPS-ML without type I IFNs, significantly reduced the number of live SK-MEL28 cells compared to the untreated cells (p < 0.05) (Fig. 3B and C) . The expression of IFNβ in the iPS-ML enhanced the inhibitory effects against the growth of SK-MEL28 cells (Fig. 3C ), but the iPS-ML-IFNα did not have these effects. One possible reason for these results may be the differences in the sensitivity of the SK-MEL28 cells to IFNα and IFNβ (Fig. 2) .
Anticancer activity in SCID mice
We then examined the in vivo anticancer effects of iPS-ML expressing either IFNα or IFNβ. SCID mice were intraperitoneally (i.p.) injected with luciferase-expressing SK-MEL28 cells (Fig. 4) . On day 3, the mice underwent a luminescence image analysis to evaluate the effects of the treatments (Fig. 4A) . Cancer cell growth in vivo was not inhibited by treatment with iPS-ML. In contrast, iPS-ML-IFNα, iPS-ML-IFNβ, and iPS-ML-IFNα plus iPS-ML-IFNβ significantly inhibited the growth of the tumors (P < 0.05) (Fig. 4B) . These results indicated that iPS-ML did not exhibit significant anticancer effects in vivo; however, genetic modification to produce type I IFNs conferred anticancer activity on the iPS-ML.
Additionally, we noted differences in cytokine expression between the iPS-ML and the iPS-ML expressing type I IFNs, with the use of an ELISA of the culture supernatants. Cytokines that can enhance the activity of macrophages, including IL6, IL8, MCP-1, RANTES, and IP-10, were increased in the culture supernatants of iPS-ML expressing type I IFNs compared to the iPS-ML (Fig. 5 ). These results suggested one possible reason why the genetic modification to produce type I IFNs conferred significant anticancer activity on iPS-ML. 
Accumulation and infiltration of iPS-ML in established tumor tissue
Macrophage infiltration is frequently observed in clinical samples of cancer tissues 14 .
We evaluated whether or not the i.p. administered iPS-ML infiltrated cancer tissue that had been established in the peritoneal cavity of mice. In this experiment, SK-MEL28 cells were injected i.p. into SCID mice. After 15 days, the mice were subjected to a luminescence imaging analysis ( and has functional activity in mouse macrophages. As a result, we found that the endogenous M2 macrophages (positive for CD163) were increased in non-treated melanoma bearing mice in comparison to the control mice. On the other hand, M2 macrophages were decreased in the mice treated with iPS-ML-IFNα cells in comparison to the non-treated group. (Fig. 7) However, the number of M1-type macrophages (positive for CD169) did not increase after the injection of iPS-ML-IFNα cells (Fig. 7) .
These results showed that the melanoma cells engrafted in mice induced an increase in the number of endogenous M2 macrophages, and that the intraperitoneal administration of iPS-ML-IFNα cells could decrease the number of endogenous M2 macrophages. We have recently reported that melanoma-bearing patients, especially those with recurrence, have few M1-type macrophages in their regional lymph nodes (19) . It therefore makes sense to supply melanoma patients with iPS-ML cells that produce type I IFNs (M1 macrophage-like cells).
No evidence of development of malignancy from human iPS-ML in SCID mice.
We found that human iPS-ML-IFN cells had colony forming capacity in vitro.
(Supplemental Fig. S1 ) The myeloid series of cells have differentiation capability that iPS-ML-IFN cells have a colony forming capacity. We evaluated malignant tumor development from human iPS-ML-IFN cells in SCID mice for up to 12 weeks. During the observation period, the mice were healthy, and no significant difference was observed in the body weight of human iPS-ML-IFN-injected mice and control mice (Supplemental Fig. S2A ). We found no evidence of tumor formation in the organs-including lung, spleen, liver, and greater omentum-in pathological specimens from mice that were injected with human iPS-ML-IFN cells, when compared to non-injected mice. (Supplemental Fig. S2B ) Thus IPS-ML cells were rejected for at least 12 weeks after injection, allowing no malignant tumors to develop in SCID mice that were injected with human iPS-ML-IFN cells. Haga et al. reported that allogeneic recipients of TAP-deficient mouse ES cell-derived ML cells do not develop leukemia (20) . In our experiments, even in immune-deficient SCID mice, the injection of iPS-ML cells did not lead to the development of leukemia or other malignancies. We are therefore of the opinion that allogenic cell therapy is safe, because the cells will be eliminated from the host immune system. It is therefore reasonable to use allogenic cells if the allogenic cell therapy is able to induce antitumor activity. 
Discussion
We herein demonstrated that iPS-ML expressing type I IFNs inhibited the growth of SK-MEL28 melanoma in xenograft models. We also found that genetic modification of the iPS-ML to produce type I IFNs changed their characteristics from exerting pro-tumor into anticancer activity. Macrophage infiltration is frequently observed in clinical samples of solid cancers, and these macrophages are called TAM, which are involved in tumor cell proliferation and tumor development (21, 22) . TAM are affected by the cancer microenvironment, including tumor-derived molecules, such as IL10 and TGFβ, and become polarized to the M2 phenotype, which reduces the adaptive Th1 response by producing anti-inflammatory factors, including IL10 and TGF , and promoting angiogenesis (14, 18, 23) .
To overcome the influence of the tumor environment and to make them exert anticancer effects, we introduced expression vectors for anticancer molecules into iPS-ML. The iPS-ML expressing type I IFNs were polarized to the M1 phenotype by the type I IFNs they produced, enabling them to maintain their M1 phenotype in the 
killer T cell activation (24, 25) . They also could infiltrate into the tumor tissue and exert anticancer effects in local tumor tissue in vivo. In this study, iPS-ML expressing IFNβ inhibited SK-MEL28 cell growth more potently than did the iPS-ML expressing IFNα in vitro and in vivo. One reason for these results may be the differences in sensitivity of the SK-MEL28 cells to IFNα and IFNβ (Fig. 3) . Another possible reason may be the differences in tissue affinity between IFNα and IFNβ. IFNβ is more lipophilic than IFNα, and therefore, may possess greater tissue affinity (8, 26) .
IFNα has been used as an adjuvant therapy after the resection of primary melanoma in many countries. High-dose IFNα adjuvant therapy is beneficial in terms of disease-free survival (DFS) in high-risk resected primary melanoma patients. In Japan, the local injection of IFNβ for the treatment of skin metastasis has been approved. Type The data are presented as the mean ± SD of triplicate assays. The P-values were determined using the Bonferroni's t test. * P < 0.05. We analyzed the cell surface molecule expression of endogenous macrophages from the greater omentum and spleen by a flow cytometric analysis using anti-mouse CD169-and CD163-specific antibodies. We analyzed three groups: the non-melanoma bearing (control) group, the non-treated melanoma bearing group and the iPS-ML-IFNα-treated melanoma bearing group. 
